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Abstract
Aims/hypothesis We used recently confirmed type 2 diabe-
tes gene regions to investigate the genetic relationship
between type 1 and type 2 diabetes, in an average of 7,606
type 1 diabetic individuals and 8,218 controls, providing
>80% power to detect effects as small as an OR of 1.11 at a
false-positive rate of 0.003.
Methods The single nucleotide polymorphisms (SNPs)
with the most convincing evidence of association in 12
type 2 diabetes-associated gene regions, PPARG, CDKAL1,
HNF1B, WFS1, SLC30A8, CDKN2A–CDKN2B, IGF2BP2,
KCNJ11, TCF7L2, FTO, HHEX–IDE and THADA, were
analysed in type 1 diabetes cases and controls. PPARG and
HHEX–IDE were additionally tested for association in
3,851 type 1 diabetes families. Tests for interaction with
HLA class II genotypes, autoantibody status, sex, and age-
at-diagnosis of type 1 diabetes were performed with all 12
gene regions.
Results Only PPARG and HHEX–IDE showed any evidence
of association with type 1 diabetes cases and controls (p=
0.004 and p=0.003, respectively; p>0.05 for other SNPs).
The potential association of PPARG was supported by family
analyses (p=0.003; pcombined=1.0×10
−4). No SNPs showed
evidence of interaction with any covariate (p>0.05).
Conclusions/interpretation We found no convincing genet-
ic link between type 1 and type 2 diabetes. An association
of PPARG (rs1801282/Pro12Ala) could be consistent with
its known function in inflammation. Hence, our results
reinforce evidence suggesting that type 1 diabetes is a
disease of the immune system, rather than being due to
inherited defects in beta cell function or regeneration or
insulin resistance.
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Abbreviations
GWA Genome-wide association
IA-2 Insulinoma-associated antigen 2
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T1DGC Type 1 Diabetes Genetics Consortium
TPO Thyroid peroxidase
WTCCC Wellcome Trust Case Control Consortium
Introduction
The possible relationship between type 1 and type 2
diabetes is a controversial subject. Formally, the two are
considered to be aetiologically distinct. Type 1 diabetes is
characterised by autoimmune destruction of pancreatic beta
cells, resulting in a failure to produce insulin. Type 2
diabetes is caused by impaired beta cell function and
capacity to secrete insulin, coupled to a decline in tissue
sensitivity to insulin. Owing to similarities in their clinical
manifestation, especially in a form of type 1 diabetes
Diabetologia (2009) 52:2109–2116
DOI 10.1007/s00125-009-1391-y
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-009-1391-y) contains supplementary material,
which is available to authorised users.
S. M. Raj:J. M. M. Howson:N. M. Walker: J. D. Cooper:
D. J. Smyth:S. F. Field: H. E. Stevens: J. A. Todd (*)
Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes
and Inflammation Laboratory,
Cambridge Institute for Medical Research,
University of Cambridge,
Wellcome Trust/MRC building, Hills Road,
Cambridge CB2 0XY, UK
e-mail: john.todd@cimr.cam.ac.ukdiagnosed in adulthood (latent autoimmune diabetes in
adults), it has been suggested that type 1 and type 2
diabetes may share a common pathophysiological aetiology
[1–3]. Therefore, we sought to investigate this hypothesis
by investigating if genetic variants that predispose individ-
uals to type 2 diabetes risk are associated with type 1
diabetes.
Currently, due mainly to the success of genome-wide
association (GWA) studies, there are 18 confirmed type 2
diabetes loci: PPARG, CDKAL1, HNF1B, WFS1, SLC30A8,
CDKN2A–CDKN2B, IGF2BP2, KCNJ11, TCF7L2, FTO,
HHEX–IDE, JAZF1, CDC123-CAMK1D, TSPAN8-LGR5,
THADA, ADAMTS9, NOTCH2 and, most recently, KCNQ1
[4–16] (Electronic supplementary material [ESM] Tables 1
and 2). Six of these regions were identified in a meta-
analysis that combined three GWA studies, and were
confirmed in an independent set of up to 14,157 cases
and 43,209 controls, by Zeggini et al. [5] (ESM Table 2).
The effects of the 18 chromosome regions on type 2
diabetes risk have ORs ranging from 1.09 to 1.37 using
single nucleotide polymorphisms (SNPs) [4–16] (Table 1;
ESM Tables 1 and 2).
We have previously evaluated the association of five
type 2 diabetes gene regions with type 1 diabetes. The gene
regions KCNJ11, IRS1 and PPARG were analysed in 2,434
type 1 diabetes families, and the PPARG rs1801282
(Pro12Ala) variant was found to have a RR of 0.87, p=
0.008 [17]. In two recent studies, TCF7L2 and FTO showed
no evidence of association with type 1 diabetes in
approximately 6,000 cases and 7,000 controls [18, 19].
We have now expanded the size of our sample sets to
maximise the statistical power of our study: we have, in
theory, 89% power to find effects as small as an OR of 1.11
at an α level of 0.003 for the mean minor allele frequency
(MAF) of 0.28 in 7,606 cases and 8,218 controls, assuming
a multiplicative model. The present study, therefore, is a
comprehensive analysis of 12 known type 2 diabetes loci,
including tests of interactions with HLA class II genotypes,
using the HLA-DRB1*03-a n dHLA-DRB1*04-tagging
SNPs rs7454108 and rs2187668, age-at-diagnosis of type
1 diabetes, sex and autoantibody status, to evaluate whether
type 1 and type 2 diabetes share a common genetic
background.
Methods
Case–control samples An average of 7,606 British type 1
diabetes cases and 8,218 British controls, all of whom were
of white ethnicity, were genotyped. Type 1 diabetes cases
were recruited for the Juvenile Diabetes Research Founda-
tion/Wellcome Trust Diabetes and Inflammation Labora-
tory’s Genetic Resource Investigating Diabetes British, type
1 diabetes collection (http://www.childhood-diabetes.org.
uk/grid.shtml, accessed 22 April 2009). Cases had been
diagnosed with type 1 diabetes before 17 years of age
(mean age at diagnosis 7.8 years). Control DNA samples
came from the British 1958 Birth Cohort (n=7,733) and the
Wellcome Trust Case Control Consortium’s (WTCCC) UK
Blood Service sample collection (n=3,181) [20]. Cases and
controls were matched in terms of place of recruitment and
place of birth, respectively, for each of 12 geographical
regions across Great Britain (southern England, south-
western England, south-eastern England, eastern England,
London, Midlands, Wales, north-eastern England, north
Midlands, East and West Ridings, northern England and
Scotland) to minimise bias in our association results owing
to varying disease prevalence and allele frequencies across
Great Britain [20, 21]. The appropriate ethics committees
approved the collection of all DNA samples, and written
consent was obtained from all individuals, or from the
parents of individuals who were too young to provide
consent.
Family samples One SNP in PPARG (rs1801282) and one
in the HHEX–IDE region (rs1111875) were genotyped in
3,851 type 1 diabetes families of white European descent.
The total comprised 593 multiplex (affected sib-pair)
families from the Diabetes UK Warren I collection; 80
simplex families from Yorkshire, UK; 263 multiplex/
simplex families from Northern Ireland; 331 multiplex
families from the Human Biological Data Interchange,
USA; 951 multiplex/simplex families from Finland; 410
simplex families from Romania; 357 simplex families from
Norway and 866 affected sib-pair families made available
through the Type 1 DiabetesG e n e t i c sC o n s o r t i u m
(T1DGC; http://www.t1dgc.org, accessed 22 April 2009;
http://www-gene.cimr.cam.ac.uk/todd/dna-refs.shtml,
accessed 22 April 2009). Of the T1DGC families, 166
families were from the Asia–Pacific region, 422 families
were from across Europe and 278 were from North
America.
Genotyping Samples were genotyped by personnel blind
to case–control status using the Taqman 5′ nuclease
assay (Applied Biosystems, Warrington, UK) according
to the manufacturer’s protocol. To minimise error, two
operators independently scored the genotypes. Previously
published genotypes at FTO, TCF7L2 and PPARG were
also included [17–19] as a subset of our present dataset.
The present study includes up to 3,363 additional type 1
diabetes cases and controls. A full description of geno-
types common to the current and previously published
data is provided in ESM Table 3. We genotyped a
minimum of 5,896 cases and 7,101 controls and a
maximum of 8,229 cases and 10,406 controls, depending
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were genotyped. The average success rate for sample
scoring was 96.77%, with a range of 95.20–97.75% across
the 14 SNPs (ESM Table 4). The HLA classical loci, HLA-
DRB1 and HLA-DQB1 were genotyped in a subset of type
1 diabetes case samples (n=3,312) as described previously
[22]. Two HLA class II SNPs, rs7454108 and rs2187668,
which tag the type 1 diabetes-predisposing DR3 and DR4
haplotypes, were also genotyped in the full case–control
collection [23].
Autoantibody measurements Levels of to GAD, insulinoma-
associated antigen 2 (IA-2) and thyroid peroxidase (TPO)
were measured in plasma samples. TPO autoantibody was
measured with a PLATO processor ELISA immunoassay
(Phadia, Milton Keynes, UK), using recombinant TPO
antigen standardised against the National Institute of Biolog-
icalStandards and Controlsstandardserum 66/387. GAD and
IA-2 autoantibodies were measured by the Department of
Clinical Science at the University of Bristol (Bristol, UK),
using a radioimmunoassay [24, 25]. The threshold value for
the presence of autoantibodies was taken as 85 IU/ml for
TPO (n=969 autoantibody-positive individuals), 6 WHO
units/ml for IA-2 (n=1,521 autoantibody-positive individuals),
and 14 WHO units/ml for GAD (n=1,305 autoantibody-
positive individuals) [26, 27].
Table 1 Association analysis of type 2 diabetes loci in type 1 diabetes cases and controls
Gene
region
SNP Cases,
n
Controls,
n
Minor allele, Number
of chromosomes
(allele frequency)
OR
(95% CI)
a
p
value
Power,
%
b
Power,
%
c
Type 2
diabetes
d
Cases Controls OR Ref.
TCF7L2 rs7903146
(C>T)
e
5,896 7,322 3,395
(0.29)
4,260
(0.29)
0.99
(0.94–1.05)
0.744 81 100 1.37 [8, 15]
rs12255372
(G>T)
7,776 8,847 4,421
(0.28)
5,125
(0.29)
0.97
(0.92–1.02)
0.235 92 100 1.52 [9]
CDKN2A–
B
rs10811661
(T>C)
7,634 7,148 2,754
(0.18)
2,498
(0.17)
1.03
(0.97–1.09)
0.354 68 100 0.83 [4, 8,
15]
FTO rs9939609
(T>A)
e
7,655 7,182 6,098
(0.40)
5,644
(0.39)
1.03
(0.98–1.08)
0.252 92 100 1.17 [4, 8]
KCNJ11 rs5219
(C>T)
8,058 10,406 5,772
(0.36)
7,411
(0.36)
1.02
(0.97–1.06)
0.501 97 100 1.14 [8, 15]
HHEX–
IDE
rs1111875
(G>A)
7,968 9,675 6,369
(0.40)
8,042
(0.42)
0.94
(0.90–0.98)
0.003 97 100 0.88 [4, 8,
15]
IGF2BP2 rs4402960
(G>T)
7,554 7,101 4,755
(0.31)
4,546
(0.32)
0.98
(0.93–1.03)
0.457 89 99 1.14 [4, 8,
15]
CDKAL1 rs7756992
(A>G)
7,714 7,200 4,185
(0.27)
3,893
(0.27)
1.00
(0.95–1.05)
0.957 86 100 1.20 [11]
SLC30A8 rs13266634
(C>T)
7,680 7,200 4,879
(0.32)
4,463
(0.31)
1.04
(0.99–1.09)
0.146 89 93 0.89 [4, 8,
15]
WFS1 rs10010131
(G>A)
7,745 9,259 6,173
(0.40)
7,564
(0.41)
0.96
(0.92–1.00)
0.065 96 96 0.90 [12]
HNF1B rs7501939
(C>T)
7,712 7,217 6,249
(0.41)
5,800
(0.40)
1.01
(0.97–1.06)
0.554 93 85 1.10 [13]
PPARG rs1801282
(C>G)
8,229 9,342 1,880
(0.11)
2,304
(0.12)
0.91
(0.85–0.97)
0.004 60 82 0.88 [4, 8,
15]
THADA rs7578597
(T>C)
7,601 8,395 1,598
(0.11)
1,840
(0.11)
0.94
(0.88–1.01)
0.113 50 80 0.87 [5]
rs17031005
(A>G)
7,256 8,760 1,481
(0.10)
1,878
(0.11)
0.94
(0.87–1.01)
0.078 50 80 NA –
aThe ORs and 95% CIs are for the minor allele using the common allele as the reference allele
bPower calculated for an OR of 1.11 at an α level of 0.003, assuming a multiplicative allelic effects model, given the allele frequency and number
of type 1 diabetes cases and controls genotyped
cPower calculated for the size of effect detected in type 2 diabetes at an α level of 0.003, assuming a multiplicative allelic effects model, using the
number of type 1 diabetes cases and controls genotyped
dThe ORs are those reported in the literature for an association with type 2 diabetes
eNew analyses of previously published data [18, 19] are included for information (ESM Table 3)
CDKN2A–B denotes CDKN2A–CDKN2B
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were performed using Stata version 10 (http://www.stata.
com, accessed 22 April 2009), using routines available
from http://www-gene.cimr.cam.ac.uk/clayton/software/
stata/ (accessed 22 April 2009). We calculated power
assuming a multiplicative effects model and an α level of
0.003, as this is equivalent to an α level of 0.05 divided by
17, the number of gene regions considered in the present
report. All SNP genotypes were in Hardy–Weinberg
equilibrium in the controls (p≥0.07) and the parents (p≥
0.06). SNPs were tested for association using logistic
regression with disease status as the dependent variable
and the SNP to be tested coded 0, 1 or 2, corresponding to
counts of the minor allele, as the predictor variable.
Geographical region was included in the logistic model as
strata within which SNP associations could be tested. To
test which inheritance model was appropriate, we compared
a multiplicative allelic effects model with a model that did
not assume a specific mode of inheritance using a
likelihood ratio test. The multiplicative model was appro-
priate for all SNPs (p≥0.08). No correction was made for
multiple comparisons.
The SNPs were tested for association in the families
using the transmission disequilibrium test (TDT), which
assumes a multiplicative allelic effects model. To test
whether the multiplicative allelic effects model was
appropriate, we used a conditional logistic regression model
to compare sets of offspring with matched pseudo-controls
(which consisted of the genotypes that could have been
transmitted to the offspring but were not). The SNPs were
modelled assuming no specific mode of inheritance, and
were compared with the allelic effects model with a
likelihood ratio test [28]. The multiplicative model was
appropriate for both SNPs (p>0.4). The p values from the
association tests in the case–control set and families were
combined using Fisher’s method. At the THADA SNP,
rs17031005, we pooled information across multiple studies
using Woolf’s estimate of the common OR [29] and a Wald
test on 1 df.
Statistical methods—interaction tests We tested for non-
multiplicative interaction effects between the SNPs and
HLA class II genotypes in a case-only analysis. This test
assumes that the HLA genotypes and the SNP of interest
are conditionally independent in controls. The SNP geno-
type was entered into a regression model as the dependent
variable, the HLA genotypes as the predictor variables, and
geographical region as strata. Three different groupings of
the HLA class II genotypes were considered, and these
have been described in detail elsewhere [30]. The first
approach grouped individuals into those positive or
negative for the HLA-DRB1*03/HLA-DRB1*04 genotype
(where HLA-DRB1*03/HLA-DRB*0403 are classed as
HLA-DRB1*03/HLA-DRB1*04-negative, as were cases
carrying the HLA-DQB1*0301 allele). The second ap-
proach used genotype risk estimates produced by Koeleman
et al. [31] to categorise individuals as being at a high-,
medium- or low-risk of type 1 diabetes based on HLA
status. Third, we used recursive partitioning to divide the
individuals into type 1 diabetes cases or controls based on
their HLA class II genotype [22]. As classical HLA
genotyping data were not available for the majority of the
type 1 diabetes sample set, the SNPs rs74544108 and
rs2187668 [23], which are in strong linkage disequilibrium
with the HLA-DRB1*04 and HLA-DRB1*03 alleles (with
r
2=0.78 and r
2=0.97, respectively), were used as tags. The
genotypes (n=8,416 cases) were coded as 3/3, 3/4, 3/X,
4/4, 4/X and X/X, with 3 and 4 corresponding to
Table 2 Association of PPARG and HHEX–IDE in type 1 diabetes families
Gene
region
SNP Families,
n
Allele or
genotype
Transmitted
a, n
(%)
Not transmitted
a,
n (%)
RR (95% CI) p
value
pcombined
value
d
PPARG rs1801282 3,312 G 862 (45.0) 988 (55.0) 0.87 (0.80–0.95) 0.003
b 1.0×10
−4
C/C 3,139 (77.4) 9,176 (75.4) 1.00 (reference)
C/G 853 (21.0) 2,789 (22.9) 0.86 (0.78–0.95)
G/G 65 (1.6) 206 (1.7) 0.84 (0.62–1.15) 0.010
c
HHEX–IDE rs1111875 3,229 A 1,728 (49.8) 1,742 (50.2) 0.99 (0.93–1.06) 0.812
b 0.017
G/G 1,283 (34.8) 3,855 (34.9) 1.00 (reference)
G/A 1,788 (48.6) 5,324 (48.2) 1.01 (0.92–1.10)
A/A 611 (16.6) 1,867 (16.9) 0.98 (0.85–1.12) 0.880
c
aNote that the frequencies of genotypes in the cases and pseudo-controls are given, as well as the transmission counts from the transmission
disequilibrium test analysis
bThe p value for association from the transmission disequilibrium test, which assumes a multiplicative model
cThe p value for association from the 2 df conditional logistic regression model, which does not assume a specific mode of inheritance
dThe p value obtained by combining the results of the case–control and family data set (please refer to the Methods for further details)
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sented all other HLA class II alleles excluding the alleles
HLA-DRB1*03 and HLA-DRB1*04.
A case-only analysis was performed for age-at-diagnosis
and sex, using genotype at the SNP of interest as the
predictor variable, and sex (coded as a binary variable) or
age-at-diagnosis (coded as a continuous variable) as the
outcome variable in a regression model (logistic regression
for sex and linear regression for age-at-diagnosis). We also
tested all SNPs for interaction with age-at-diagnosis divided
into quartiles (0–4, 5–7, 8–10 and 11–16 years), using
multinomial logistic regression. Interactions between the
autoantibodies and SNP genotype were also tested in the
cases. Each autoantibody was coded as a binary trait,
corresponding to the presence or absence of the autoanti-
body, and was used as the dependent variable in a logistic
model, with genotype at the test locus as the independent
variable [27].
Results
The results of the association tests are summarised in
Table 1. We found no convincing evidence of association
between the type 1 and type 2 diabetes candidate genes in
the case–control dataset, with the possible exceptions of
PPARG (rs1801282 p=0.004, OR [95% CI] 0.91 [0.85–
0.97]) and HHEX–IDE (rs1111875, p=0.003, OR [95% CI]
0.94 [0.90–0.98]) (Table 1; ESM Table 4). Hence, these two
SNPs were further genotyped in a minimum of 3,229
families. The PPARG SNP rs1801282 had already been
genotyped in a subset (n=2,355) of these families [17]
(ESM Table 3). By genotyping an additional 1,135 families
the power for the detection of associations was increased.
The result we obtained for the SNP rs1801282 in the
families was consistent with that obtained in the case–
control collection (p=0.003, RR [95% CI] 0.87 [0.80–
0.95]; Table 2; pcombined=1×10
−4). We obtained no
additional support for an association of HHEX–IDE (p=
0.812, RR [95%CI] 0.99 [0.93–1.06]; Table 2) with type 1
diabetes in the families. Although none of these SNPs
showed a convincing association with type 1 diabetes
overall, we were interested in whether they may affect a
subgroup of type 1 diabetes cases. Therefore, we tested for
interaction between all the SNPs and HLA class II
genotypes, autoantibody status, age-at-diagnosis and sex.
We found no evidence of interaction effects between the
HLA genotypes and the type 2 diabetes loci (p>0.02)
(ESM Table 5). We also found no evidence for an
interaction between any of the autoantibodies and the type
2 diabetes SNPs (p≥0.05). This included the SLC30A8 SNP
rs13266634, which has been reported by Hutton and
colleagues [32] to determine the specificity of ZnT8, a
newly discovered type 1 diabetes autoantigen [33].
No evidence of interactions with age-at-diagnosis or sex
with the SNP association with type 1 diabetes was found
(p≥0.05). Gohlke et al. [34] reported an association
between early age-at-diagnosis (<5 years of age) and the
SLC30A8 SNP rs13266634, and Wenzlau et al. [33] showed
that ZnT8 autoantibodies appear before 3 years of age.
Therefore, we also tested for interactions between the type
2 diabetes loci and age-at-diagnosis divided into quartiles,
which included a group of individuals under 4 years of age,
and found no evidence of interactions between age at
diagnosis and the type 2 diabetes loci over any of the four
age groups (p>0.04; ESM Table 6), except for some
evidence at CDKN2A–CDKN2B (rs10811661 p=0.008;
ESM Table 6), which is unlikely to be a true result, taking
into account the number of hypotheses tested.
Six recently reported type 2 diabetes gene regions,
JAZF1, CDC123–CAMK1D, TSPAN8–LGR5, THADA,
ADAMTS9 and NOTCH2, identified by a meta-analysis
published by Zeggini et al. [5], were also analysed for
association with type 1 diabetes in a meta-analysis by
Cooper et al. [35] (results for nine type 2 diabetes-
associated SNPs, from the Cooper et al. type 1 diabetes
meta-analysis are given in ESM Table 2). The Cooper et al.
[35] meta-analysis combined GWA data (305,090 SNPs)
for 1,964 British type 1 diabetes cases and 2,953 controls
from the WTCCC study [20] with data for 1,601 US type 1
diabetes cases from the Genetics of Kidneys in Diabetes
study and 1,704 US controls from the National Institute of
Mental Health [35], and hence included up to 3,565 cases
and 4,657 controls. Three SNPs with the most convincing
evidence of association with type 2 diabetes from these six
regions published by Zeggini et al. [5] were not included in
the type 1 diabetes meta-analysis. However, substitutes in
linkage disequilibrium with these type 2 diabetes SNPs
(r
2>0.8 in the HapMap (http://www.hapmap.org, accessed
22 April 2009) Centre d’Etude du Polymorphisme Humain
[CEPH] panel of 32 individuals) were included (ESM
Table 2).
Only the THADA SNP rs17031005, which is in linkage
disequilibrium with the type 2 diabetes-associated SNP
rs7578597 in the THADA gene region (r
2=1), showed
evidence of association with type 1 diabetes in the meta-
analysis by Cooper et al. [35]( p=4.79×10
−5; ESM Table 2).
Therefore, we followed up this result by genotyping
rs17031005 in 7,256 cases and 8,760 controls, and the
type 2 diabetes-associated SNP rs7578597 in 7,601 British
type 1 diabetes cases and 8,395 controls. The genotypes of
samples, which were used by both the WTCCC and the
present study, were compared at rs17031005 and revealed
99.9% concordance between the studies. We found no
evidence of association with type 1 diabetes at rs17031005
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were not included in the type 1 diabetes meta-analysis by
Cooper et al. [35] or in the full dataset of 7,256 cases and
8,760 controls (p=0.078; Table 1). Similarly, rs7578597
was not associated with type 1 diabetes (p=0.113). As we
found no association with type 1 diabetes, the type 1
diabetes meta-analysis result in the THADA gene region is
likely to be a false-positive result [35] (ESM Table 2).
Finally, a meta-analysis combining the 5,442 cases and
6,239 controls genotyped in the present study with the
WTCCC and the US studies used by Cooper et al. [35]
provided no additional support for association with type 1
diabetes at rs17031005 (p=0.003). Furthermore, we found
no evidence of interactions between the THADA SNPs and
HLA class II genotypes (p>0.05; ESM Table 5), age-at-
diagnosis (p>0.05; ESM Table 6), sex or autoantibody
status (p>0.05).
Discussion
We have investigated confirmed type 2 diabetes-associated
SNPs for association with type 1 diabetes and interaction
with sex, age-at-diagnosis, HLA class II genotypes and
autoantibody status in a dataset larger than any previously
published study. Yet, we have failed to find evidence of
association between type 1 diabetes and these confirmed
loci, with the possible exception of the PPARG rs1801282
SNP. As the controls represent the British population, we
expect approximately 3.4% to have or to develop type 2
diabetes (http://www.diabetes.org.uk/Professionals/Infor
mation_resources/Reports/Diabetes-prevalence-2008/,
accessed 22 April 2009). However, this only led to a very
small loss of power (<1%). Indeed, at the PPARG SNP, we
had 87% power to exclude an effect as small as an OR of
1.14 at an α level of 0.003 and a MAF of 0.12, while a
recently published negative study analysing SNP
rs2197423 in PPARG was powered to exclude effects with
an OR of greater than 1.34 [36]. Hence, the present study
was statistically well powered to detect effects as small as
those reported for type 2 diabetes but was not powered to
exclude effects with an OR of below 1.11 (Table 1).
The transcription factor PPARγ has been reported to
have effects in type 2 diabetes, in the immune system, and
in inflammation, as evidenced by its production in several
types of immune cell. In macrophages, PPARγ regulates
lipid metabolism and controls the inflammatory response,
while in T cells it inhibits IL-2 secretion and can induce
apoptosis. Type 2 diabetes treatments that act by binding to
PPARγ, which belong to the thiazolidinedione class of
drugs, have been investigated in the treatment of several
autoimmune diseases. Human psoriasis cases showed
reduced plaque formation when treated with pioglitazone
[37]. PPARγ may have multiple targets in rheumatoid
arthritis (RA), as it regulates the key RA mediators TNF-α,
IL-1β a n dI L - 6[ 38]. Troglitazone reduced adjuvant-
induced arthritis in the Lewis rat model [39], and
rosiglitazone reduced colitis in a murine model of inflam-
matory bowel disease [38, 40]. More specifically, the larger
of the two PPARγ isoforms (γ2) is the only one to express
the region of the gene containing the rs1801282/Pro12Ala
SNP. This isoform is predominantly expressed in fat cells.
An increase in the production of the Ala12 variant of the γ2
isoform, which confers a 25% reduced risk of type 2
diabetes, is known to improve insulin sensitivity [41].
Improved insulin sensitivity could provide some protection
against type 1 diabetes.
Wenzlau et al. [33] found that SLC30A8, which encodes
the ZnT8 autoantigen, is highly expressed in the pancreas.
They also reported that antibodies to ZnT8 are detectable at
a very young age in type 1 diabetic patients, frequently
before 3 years [33]. Wenzlau et al. [32] later identified
rs13266634 as the SNP responsible for the type 1 diabetes
autoimmune response to ZnT8 [32]. In contrast to the
findings of Wenzlau et al. [32, 33] and Gohlke et al. [34],
our results suggest that altering the specificity of the
ZnT8 autoantibody via SLC30A8 SNP rs13266634 does
not alter the risk of type 1 diabetes, even in individuals
diagnosed with type 1 diabetes at a very young age
(0–4 years) (ESM Table 6), or by HLA class II genotype
(ESM Table 5).
Whilst we have investigated SNPs in 12 of the type 2
diabetes-associated gene regions for association with type
1 diabetes, it is possible that these regions also contain
type 1 diabetes causal variants that do not affect type 2
diabetes. However, this is not evident in the results from
the meta-analysis of up to 3,565 type 1 diabetes cases and
4,657 controls [35]. Equally, as these SNPs explain less
than 10% of genetic variation [42] in type 2 diabetes risk,
there may be undiscovered type 2 diabetes loci associated
with type 1 diabetes. Finally, as all our type 1 diabetic
patients were paediatric cases, we cannot rule out the
possibility that type 2 diabetes genes affect adult-onset type
1 diabetes. One recent report suggested that TCF7L2 may
be associated with latent autoimmune diabetes in adults, a
form of type 1 diabetes that is diagnosed in individuals
aged >35 years [2]. This result, however, may have been
due to a small number of type 2 diabetes cases included in
the study [43]. Our results, and those of a recent study of
type 1 diabetes loci in type 2 diabetes cases and controls
[44], nevertheless indicate that type 2 diabetes susceptibility
loci do not make a substantial contribution to the risk of
paediatric type 1 diabetes.
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